Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan

Journal of Clinical Hypertension

Volumn 17, Issue 1, 2015, Pages 51-58

  Tung, Ying Chang ^a   Lin, Yu Sheng ^a   Wu, Lung Sheng ^a   Chang, Chee Jen ^a   Chu, Pao Hsien ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; AMLODIPINE; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; DISEASE FREE SURVIVAL; DRUG COST; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR ADVERSE CARDIOVASCULAR EVENT FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; ECONOMICS; FOLLOW UP; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AGED; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYPERTENSION; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84921026181     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12449     Document Type: Article

References (30)

1. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
2. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
3. Trialists' Collaboration BPLT. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
4. Trialists' Collaboration BPLT. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410.
5. Staessen JA, Li Y, Thijs L, Wang J-G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
7. Su T-C, Bai C-H, Chang H-Y, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens. 2008;26:600-606.
8. Sanson-Fisher R, Clover K. Compliance in the treatment of hypertension: a need for action. Am J Hypertens. 1995;8:82S-88S.
9. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11:376-382.
10. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep. 2002;4:424-433.
11. Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2008;10:751-760.
12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.
14. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents a meta-analysis. Hypertension. 2010;55:399-407.
15. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
17. d'Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
18. Malesker M, Hilleman D. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care. 2010;19:36.
19. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324-332.
20. Wu PH, Yang CY, Yao ZL, et al. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens. 2010;23:155-160.
21. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
22. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836.
23. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;2:144-151.
24. Lang K, Meyers J, Korn J, et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010;61:1239-1247.
25. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605.
26. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-3035.
27. Shin S, Song H, Oh S-K, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36:1000-1005.
28. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610-618.
29. Sicras Mainar A, Galera Llorca J, Munoz Orti G, Navarro Artieda R. Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension. Med Clin. 2011;136:183-191.
30. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918-929.